Comparative Pharmacology
Head-to-head clinical analysis: IOSAT versus TAPAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOSAT versus TAPAZOLE.
IOSAT vs TAPAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks thyroidal uptake of radioactive iodine isotopes, reduces thyroid exposure to radiation by saturating thyroid gland with stable iodine.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4) and reducing iodine organification and coupling of iodotyrosines.
Adults: 130 mg orally once daily for potassium iodide (SSKI 1 g/mL). For thyroid protection in radiation exposure: 130 mg orally once, may repeat after 24 hours if necessary.
15-40 mg per day orally in 3 divided doses; maintenance: 5-15 mg per day orally once daily.
None Documented
None Documented
3-5 days in euthyroid individuals; prolonged in hyperthyroidism (6-12 days) and renal impairment (up to 30 days)
3-6 hours; clinically, effects persist longer due to intrathyroidal accumulation.
Renal: >99% as iodide; fecal/biliary: <1%
Primarily renal, approximately 65% excreted in urine as metabolites and unchanged drug; <10% eliminated in feces via biliary excretion.
Category C
Category C
Antithyroid Agent
Antithyroid Agent